Pure Global
NCT03134222

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Gilead Sciences·Phase 2·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cutaneous Lupus Erythematosus
Drug/Device/Intervention
Lanraplenib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Gilead Sciences
Location
Beverly Hills,Fullerton,Los Angeles,Palm Desert,San Diego,Upland,Clearwater,DeBary,Charlotte,Winston-Salem,Hershey,Philadelphia,Dallas,Ottawa,Toronto,Waterloo, Canada,United States of America
Timeline & enrollment
Phase
Phase 2
Start date
May 24, 2017
End date
Dec 18, 2019
Enrollment
47 participants
Primary outcome

Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12

Summary

The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib
 (formerly GS-9876) in females with moderately-to-severely active cutaneous lupus
 erythematosus (CLE).

ICD-10 classifications
Subacute cutaneous lupus erythematosusLupus erythematosusDiscoid lupus erythematosusSystemic lupus erythematosusSystemic lupus erythematosus, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03134222
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03134222 through Pure Global AI's free database. This Phase 2 trial is sponsored by Gilead Sciences and is currently Completed. The study focuses on Cutaneous Lupus Erythematosus. Target enrollment is 47 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.